Cargando…
Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells
The complete regression of clear cell renal cell carcinoma (ccRCC) obtained pre-clinically with anti-carbonic anhydrase IX (CAIX) G36 chimeric antigen receptor (CAR) T cells in doses equivalent to ≅10(8) CAR T cells/kg renewed the potential of this target to treat ccRCC and other tumors in hypoxia....
Autores principales: | de Campos, Najla Santos Pacheco, de Oliveira Beserra, Adriano, Pereira, Pedro Henrique Barbosa, Chaves, Alexandre Silva, Fonseca, Fernando Luiz Affonso, da Silva Medina, Tiago, dos Santos, Tiago Goss, Wang, Yufei, Marasco, Wayne Anthony, Suarez, Eloah Rabello |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141239/ https://www.ncbi.nlm.nih.gov/pubmed/35628256 http://dx.doi.org/10.3390/ijms23105448 |
Ejemplares similares
-
Carbonic Anhydrase IX: A Renewed Target for Cancer Immunotherapy
por: de Campos, Najla Santos Pacheco, et al.
Publicado: (2022) -
Carbonic anhydrase IX in oligodendroglial brain tumors
por: Järvelä, Sally, et al.
Publicado: (2008) -
Targeting Carbonic Anhydrase IX Activity and Expression
por: Mahon, Brian P., et al.
Publicado: (2015) -
Carbonic Anhydrase IX—Mouse versus Human
por: Takacova, Martina, et al.
Publicado: (2019) -
Carbonic anhydrase IX and acid transport in cancer
por: Becker, Holger M.
Publicado: (2019)